VANCOMYCIN HYDROCHLORIDE Drug Patent Profile

Which patents cover Vancomycin Hydrochloride, and what generic alternatives are available?

Vancomycin Hydrochloride is a drug marketed by Fresenius Kabi Usa, Lupin, Orient Pharma Co Ltd, Pai Holdings, Strides Pharma, Watson Labs, Alkem Labs Ltd, Amneal, Aspiro, Avet Lifesciences, Eugia Pharma, Eurofarma, Gland, Hikma, Hikma Pharms, Hospira, Hospira Inc, Knack, Meitheal, Mylan Labs Ltd, Plano Pharms, Sagent Pharms, Slate Run Pharma, Teva Pharms Usa, Xellia Pharms Aps, Samson Medcl, Steriscience, Zhejiang Novus Pharm, and Baxter Hlthcare. and is included in fifty-four NDAs.

The generic ingredient in VANCOMYCIN HYDROCHLORIDE is vancomycin hydrochloride. There are twenty-two drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the vancomycin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vancomycin Hydrochloride

A generic version of VANCOMYCIN HYDROCHLORIDE was approved as vancomycin hydrochloride by FRESENIUS KABI USA on March 17^th, 1987.

Summary for VANCOMYCIN HYDROCHLORIDE

US Patents:	0
Applicants:	29
NDAs:	54
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VANCOMYCIN HYDROCHLORIDE

Paragraph IV (Patent) Challenges for VANCOMYCIN HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FIRVANQ KIT	For Oral Solution	vancomycin hydrochloride	25 mg/mL and 50 mg/mL	208910	1	2020-05-18

US Patents and Regulatory Information for VANCOMYCIN HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Plano Pharms	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	INJECTABLE;INJECTION	090250-001	Apr 27, 2010		DISCN	No	No
Mylan Labs Ltd	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	POWDER;INTRAVENOUS	209481-002	Jul 10, 2018	AP	RX	Yes	Yes
Hikma	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	INJECTABLE;INJECTION	204360-002	Oct 15, 2018	AP	RX	No	No
Fresenius Kabi Usa	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	INJECTABLE;INJECTION	062663-005	Aug 17, 2016	AP	RX	No	No

Vancomycin Hydrochloride Investment and Fundamentals Analysis

Last updated: February 20, 2026

What is the current market landscape for vancomycin hydrochloride?

Vancomycin hydrochloride is a glycopeptide antibiotic effective primarily against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It holds critical importance in hospital settings for treating severe infections. The global market’s value was estimated at approximately USD 1.5 billion in 2022, with a compound annual growth rate (CAGR) of around 4.2%, projected to reach USD 1.9 billion by 2028 [1].

Major producers include Pfizer, Teva, and Hikma Pharmaceuticals. These companies supply both branded and generic formulations. Demand growth is driven by rising antimicrobial resistance, increasing hospital-acquired infections, and expanding healthcare infrastructure in emerging markets.

What are the key factors influencing investment decisions?

Market Drivers

• Rising antimicrobial resistance: Growing cases of MRSA and resistant infections elevate demand.
• Hospital infection control protocols: Increased use in intensive care units, surgeries, and immunocompromised patients.
• Regulatory approvals for new formulations: New delivery methods or combination therapies can extend product lifecycles.

Market Challenges

• Generic drug competition: High patent expiry rates have increased generic availability, compressing margins.
• Manufacturing complexity: Requires specialized fermentation and purification processes, impacting production costs.
• Regulatory scrutiny: Changes in prescribing guidelines or manufacturing standards may affect supply stability.

Supply Chain and Manufacturing

• Raw materials: Vancomycin production relies on specific fermentation substrates, which can be subject to supply disruptions.
• Production capacity: Key producers have invested in plant upgrades to meet rising global demand.
• Quality standards: Strict compliance with Good Manufacturing Practices (GMP) influences market access and costs.

Regulatory Environment

• Clearance from agencies like the FDA and EMA is essential for sale in North America and Europe.
• Recent guidance emphasizes antimicrobial stewardship, potentially affecting prescribing patterns.

Patent and Pricing Trends

• Most formulations are now off-patent, leading to increased generics.
• Price pressures exist due to multiple market players and competitive bidding in hospital procurement.

R&D and Pipeline Developments

• Few novel formulations or delivery systems are in late-stage development.
• Yet, efforts target combination therapies and improved bioavailability, offering potential differentiation.

What is the investment outlook based on fundamentals?

Aspect	Assessment
Market Size & Growth	USD 1.5 billion in 2022; 4.2% CAGR; projected USD 1.9 billion by 2028
Competitive Landscape	Dominated by generics; high price erosion risk
Innovation Potential	Limited new formulations; R&D focused on combinations and delivery systems
Regulatory Risks	Stable but evolving; stewardship policies may impact prescribing patterns
Manufacturing Barriers	Complex fermentation, supply chain, GMP standards

Investment Opportunities

• Companies with established manufacturing capacity and compliance can benefit from rising demand.
• Emerging-market expansion offers growth potential but requires navigation of regulatory complexity.
• Investing in firms developing proprietary delivery methods or combination drugs could provide competitive advantages.

Investment Risks

• Price erosion due to generics limits margin expansion.
• Disruptions in raw material supply can impact production.
• Regulatory changes toward antimicrobial stewardship may limit market size.

What are key takeaways for investors?

• The vancomycin hydrochloride market remains vital amid antimicrobial resistance challenges.
• Margins are under pressure from generic competition, but growth persists.
• Limited pipeline or innovation reduces upside unless new formulations or delivery systems gain approval.
• Regulatory stability supports ongoing supply, but stewardship policies could influence usage.
• Regional expansion presents a chance but involves regulatory and competitive risks.

FAQs

1. What are the main growth drivers for vancomycin hydrochloride?
Antimicrobial resistance and increased hospital infections drive demand, especially in regions with expanding healthcare infrastructure.

2. How does patent expiry impact the market?
Patent expiry for vancomycin has led to a surge in generic manufacturers, increasing competition and reducing prices.

3. Are there new formulations or delivery methods in development?
Limited late-stage development exists; most efforts focus on combination therapies and improved delivery systems.

4. What regulatory considerations are relevant?
Evolving antimicrobial stewardship policies influence prescribing patterns, and manufacturing must adhere to GMP standards.

5. Is there potential for value creation through innovation?
Yes, if firms develop formulations with better bioavailability or combination products, they may gain competitive advantages.

References

[1] Market Research Future. (2023). Vancomycin Hydrochloride Market Size, Share, & Trends. Retrieved from https://www.marketresearchfuture.com